SkinVive by JUVÉDERM
First FDA-approved HA microdroplet for cheek skin quality improvement
About This Treatment
SkinVive by JUVÉDERM (Allergan) is the first FDA-approved HA microdroplet specifically for skin quality improvement. Unlike volumizing fillers, SkinVive distributes micro-droplets of HA throughout the dermis to fundamentally enhance skin hydration.
VYCAA HA technology (Vycross™ derivative) crosslinks low and high molecular weight HA at optimal ratio, creating micro-reservoirs that attract water molecules for natural radiance.
Mechanism of Action
VYCAA-crosslinked modified HA distributes as micro-droplets throughout dermis. Each droplet acts as micro-reservoir attracting up to 1000x its weight in water. Sustained dermal hydration improves smoothness, moisture, and glow for 6+ months with minimal volumizing effect.
Indications
Expected Results
Single treatment provides 6+ months of skin quality improvement. Clinical trials show significant cheek smoothness score improvement. 90%+ patients report improved hydration and glow. Minimal volume change for natural results.
Clinical Evidence
Risks & Side Effects
Small bumps, redness, bruising at injection sites (resolves 1-3 days). Rare asymmetry. Very rare allergic reaction. Limited evidence for off-label use beyond cheeks.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition